» Articles » PMID: 32203172

HPV-mediated Nuclear Export of HP1γ Drives Cervical Tumorigenesis by Downregulation of P53

Abstract

E6 oncoprotein derived from high-risk human papillomavirus (HPV) drives the development of cervical cancer through p53 degradation. Because cervical cancer therapies to inactivate HPV or E6 protein are not available, alternative strategies are required. Here, we show that HPV-mediated nuclear export of human heterochromatin protein 1γ (HP1γ) reduces the stability of p53 through UBE2L3-mediated p53 polyubiquitination during cervical cancer progression. In general, HP1 plays a key role in heterochromatin formation and transcription in the nucleus. However, our immunostaining data showed that the majority of HP1γ is localized in the cytoplasm in HPV-mediated cervical cancer. We found that HPV E6 protein drives unusual nuclear export of HP1γ through the interaction between the NES sequence of HP1γ and exportin-1. The mutation of the NES sequence in HP1γ led to nuclear retention of HP1γ and reduced cervical cancer cell growth and tumor generation. We further discovered that HP1γ directly suppresses the expression of UBE2L3 which drives E6-mediated proteasomal degradation of p53 in cervical cancer. Downregulation of UBE2L3 by overexpression of HP1γ suppressed UBE2L3-dependent p53 degradation-promoting apoptosis of cervical cancer cells. Our findings propose a useful strategy to overcome p53 degradation in cervical cancer through the blockage of nuclear export of HP1γ.

Citing Articles

Precision therapeutic targets for HPV-positive cancers: an overview and new insights.

Huang Y, Wang J, Yang W, Hou F, Feng X Infect Agent Cancer. 2025; 20(1):17.

PMID: 40069817 PMC: 11900425. DOI: 10.1186/s13027-025-00641-7.


Induction of the p21/CDK6 pathway and alteration of the immune microenvironment by the stem cell marker CBX3 in melanoma.

Chen W, Zhou L, Jiang J, Chen J, Geng D, Chen Y Stem Cell Res Ther. 2025; 16(1):63.

PMID: 39934923 PMC: 11816572. DOI: 10.1186/s13287-025-04179-8.


Systematic Analysis of E3 Ligase-Related Genes Identified UBE2L3 as a Prognostic Biomarker Associated With Drug Resistance in Acute Myeloid Leukemia.

Ling C, Cao N, Wang H, Wan Y, Liang X, Guo J Int J Gen Med. 2025; 18:459-472.

PMID: 39895829 PMC: 11787778. DOI: 10.2147/IJGM.S502644.


UBE2L3 expression in human gastric cancer and its clinical significance.

Zhang X, Wei Y, Wu F, Li M, Han C, Huo C J Cancer Res Clin Oncol. 2024; 150(4):210.

PMID: 38656363 PMC: 11043109. DOI: 10.1007/s00432-024-05669-7.


Exploring the causal association between rheumatoid arthritis and the risk of cervical cancer: a two-sample Mendelian randomization study.

Xu M, Chen H, Tan T, Xie K, Xie H, Li Q Arthritis Res Ther. 2024; 26(1):35.

PMID: 38263277 PMC: 10804645. DOI: 10.1186/s13075-023-03240-2.


References
1.
Holowaty P, Miller A, Rohan T, To T . Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999; 91(3):252-8. DOI: 10.1093/jnci/91.3.252. View

2.
Durst M, Gissmann L, Ikenberg H, zur Hausen H . A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983; 80(12):3812-5. PMC: 394142. DOI: 10.1073/pnas.80.12.3812. View

3.
Smith J, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R . Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121(3):621-32. DOI: 10.1002/ijc.22527. View

4.
Hildesheim A, Herrero R, Wacholder S, Rodriguez A, Solomon D, Bratti M . Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298(7):743-53. DOI: 10.1001/jama.298.7.743. View

5.
Moore D, Tian C, Monk B, Long H, Omura G, Bloss J . Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2009; 116(1):44-9. PMC: 4470610. DOI: 10.1016/j.ygyno.2009.09.006. View